Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/814"
| Predicate | Value (sorted: none) |
|---|---|
| rdf:type | |
| rdf:type | |
| rdfs:label | |
| ?:Evidence_type | |
| ?:Evidence_enzyme_system | |
| ?:Evidence_value |
"0.29"
|
| dc:creator | |
| dc:date |
"10/20/2007 09:31:37"
|
| ?:content |
"NOTE: XR and immediate release formulations have slightly different bioavailabilities. The higer of the two was chosen (XR = 29%).
Quote:
"Following administration of a 10 mg dose, the absolute bioavailability is 24% (range 9%-50%). Administration with food reduces the rate but not the extent of absorption...Fluvastatin administered as Lescol XL 80 mg tablets reaches peak concentration in approximately 3 hours under fasting conditions, after a low-fat meal, or 2.5 hours after a low-fat meal. The mean relative bioavailability of the XL tablet is approximately 29% (range: 9%-66%) compared to that of the Lescol immediate-release capsule administered under fasting conditions. Administration of a high-fat meal delayed the absorption (Tmax: 6H) and increased the bioavailability of the XL tablet by approximately 50%. ""
|
| rdfs:seeAlso |
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ fluvastatin_bioavailability_continuous_value, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1032 }